ArticleJournal of thoracic disease2017
Clinical analysis on 113 patients with lung cancer treated by percutaneous CT-guided microwave ablation.
Article in Journal of thoracic disease, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04081181 (CT_ Guided Percutaneous Microwave Ablation in Treatment of Pulmonary Malignancies), which is not on this map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CT_ Guided Percutaneous Microwave Ablation in Treatment of Pulmonary Malignancies
Who cites it
30 citing papers in PubMed, 58 citations in OpenAlex.
- The effect of radio-frequency ablation in treating pulmonary ground glass nodule patients and its influence on pulmonary function.African health sciences · 2024Trial
- A prognostic model for predicting progression-free survival in patients with advanced non-small cell lung cancer after image-guided microwave ablation plus chemotherapy.European radiology · 2023Trial
- Effect of Comprehensive Nursing Intervention on the Effect of CT-Guided Intravenous Thrombolysis in Acute Cerebral Infarction.Journal of healthcare engineering · 2022Trial
- Microwave ablation plus chemotherapy versus chemotherapy in advanced non-small cell lung cancer: a multicenter, randomized, controlled, phase III clinical trial.European radiology · 2020Trial
- Optical characteristics of human lung cancer for photodynamic therapy with measured absorption and reduced scattering coefficients.Journal of biomedical optics · 2025Article
- Article
- Investigation of the efficacy and safety of lung biopsy plus microwave ablation for a solitary suspected malignant pulmonary nodule after radical mastectomy.Frontiers in oncology · 2025Article
- Machine learning models for predicting survival in lung cancer patients undergoing microwave ablation.Frontiers in medicine · 2025Article
- Comparative safety and efficacy of single-agent chemotherapy combined with microwave ablation versus radioactive seed brachytherapy in elderly patients with advanced NSCLC: a ten-year retrospective study.American journal of cancer research · 2025Article
- Lung imaging methods: indications, strengths and limitations.Breathe (Sheffield, England) · 2024Review
- Maintenance treatment of immunotherapy after microwave ablation plus drug-eluting bead bronchial arterial chemoembolization for advanced non-small cell lung cancer: a retrospective single-center cohort study.Quantitative imaging in medicine and surgery · 2024Article
- Denosumab combined with microwave ablation excisional scraping for giant cell tumor of the thoracic spine: a case report and literature review.Frontiers in oncology · 2024Article
- The safety and response of CT guided percutaneous cryoablation for lung nodules by 17-gauge needles.BMC medical imaging · 2023Article
- CT-based radiomics models may predict the early efficacy of microwave ablation in malignant lung tumors.Cancer imaging : the official publication of the International Cancer Imaging Society · 2023Article
- Drug-Eluting Bead Bronchial Arterial Chemoembolization With and Without Microwave Ablation for the Treatment of Advanced and Standard Treatment-Refractory/Ineligible Non-Small Cell Lung Cancer: A Comparative Study.Frontiers in oncology · 2022Article
- Image-guided percutaneous ablation for lung malignancies.Frontiers in oncology · 2022Review
- Technical and safety performance of CT-guided percutaneous microwave ablation for lung tumors: an ablate and resect study.Journal of thoracic disease · 2021Article
- Review
- Outcomes Following Percutaneous Microwave and Cryoablation of Lung Metastases from Adenoid Cystic Carcinoma of the Head and Neck: A Bi-Institutional Retrospective Cohort Study.Annals of surgical oncology · 2021Article
- Assessment of safety margin after microwave ablation of stage I NSCLC with three-dimensional reconstruction technique using CT imaging.BMC medical imaging · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLung Cancer is a primary tumor with poor prognosis. For early stage lung cancer, treatment options include surgical resection and microwave techniques. Percutaneous ablative techniques emerged as best therapeutic options for nonsurgical patients.
methodsThe aim of this study was to retrospectively analyze the clinical effect of CT-guided microwave ablation (MWA) treatment for patients with lung cancer who were not eligible for surgical resection. MWA was used to treat the tumor lesion of 113 patients with lung cancer who were in our hospital from Jan, 2013 to Jun, 2015. The median diameter of tumors was 3.1 cm (0.7-6 cm). Follow-up were paid to all the patients who received MWA therapy. The average follow-up was 22.1±8.6 months, and the median follow-up was 18 (7-40) months.
resultsAll of 113 cases of patients with lung cancer experienced MWA therapy, and their tumors were found to have vacuolization, lower density and much smaller distinct shrinkage of tumor size with varying degrees. The local progression rate or relapse rate of the whole group was 15.9%. The counterpart of patients in the early-stage group was 5.7% (2/35), and the diameter of tumors in the two patients was more than 3 cm. The local progression rate or relapse rate of patients in advanced-stage group was 20.5%, wherein, 81.3% of local progression or relapse occurred to the patients with a tumorous diameter of more than 3 cm. The results indicated that the patients in advanced-stage group were vulnerable to local progression or relapse, the tumorous with greater diameter had higher incidence of local relapse. No mortality occurred within 30 days after surgery, the survival rate of patients in early-stage group at first, second, third year was respectively 97.1%, 94.1% and 84.7%. The counterpart of patients in advanced-stage group was respectively 93.6%, 87.7% and 71.7%. The difference of survival rate between both groups was not statistically significant (P=0.576). No perioperative deaths occurred, and the main complications i.e., fever, pneumothorax, pleural effusion, hemoptysis, pneumonia, and pain were slight and tolerable.
conclusionsMWA is an effective, safe and minimally invasive treatment for the patients with lung cancer who cannot be tolerated by surgical resection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.